Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: Kinetics and structural requirements

被引:37
|
作者
Hutzler, JM [1 ]
Kolwankar, D [1 ]
Hummel, MA [1 ]
Tracy, TS [1 ]
机构
[1] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA
关键词
D O I
10.1124/dmd.30.11.1194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2C9-mediated metabolism has been shown to be activated in the presence of the effector dapsone. However, it has yet to be established what effector structural features are necessary to activate CYP2C9 activity. To address this question, kinetic studies were conducted with nine analogs of dapsone containing various functional properties (three sulfone compounds, three carbonyl compounds, and three sulfonamide compounds), to examine the functional groups important for enzyme activation by the effector (dapsone). Results show that phenylsulfone (dapsone without the para-amino groups) activates flurbiprofen 4'-hydroxylation comparable to dapsone but inhibits naproxen demethylation. Meanwhile, p-tolylsulfone had little effect on flurbiprofen metabolism, but activated naproxen demethylation, albeit only at high concentrations. These substrate-dependent differences in effect suggest that naproxen has a different binding orientation compared with flurbiprofen. Perhaps most interesting is that replacement of only one amino group from dapsone with a nitro group (4-(4-nitrophenylsulfonyl)-aniline) resulted in substantial inhibition of flurbiprofen 4'-hydroxylation, suggesting that electronic effects may influence activation of this substrate. Other analogs either had minor or no effect on CYP2C9-mediated metabolism. Overall, it is apparent from these studies that a sulfone group in direct association with two benzene rings with para-electron-donating groups represents the most efficient activator of CYP2C9. However, the effects of these analogs appear to be concentration-and substrate-dependent, further complicating the prediction of these types of in vitro interactions.
引用
收藏
页码:1194 / 1200
页数:7
相关论文
共 50 条
  • [31] Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes
    Nu He
    Wen-Qi Zhang
    Dolores Shockley
    Timi Edeki
    European Journal of Clinical Pharmacology, 2002, 57 : 847 - 851
  • [32] Prediction of CYP2C9-mediated drug-drug interactions: A comparison using data from recombinant enzymes and human hepatocytes
    McGinnity, DF
    Tucker, J
    Trigg, S
    Riley, RJ
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) : 1700 - 1707
  • [33] In Vitro Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod: Possible Mechanism of Iguratimod-Warfarin Interaction
    Yamaori, Satoshi
    Takami, Ken
    Shiozawa, Ayaka
    Sakuyama, Kanako
    Matsuzawa, Naoki
    Ohmori, Shigeru
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (03) : 441 - 447
  • [34] The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation
    Nair, Pramod C.
    Burns, Kushari
    Chau, Nuy
    Mckinnon, Ross A.
    Miners, John O.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (12)
  • [35] Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
    Guo, YJ
    Zhang, YF
    Wang, Y
    Chen, XY
    Si, DY
    Zhong, DF
    Fawcett, JP
    Zhou, H
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) : 749 - 753
  • [36] Kinetic analysis of fluvastatin metabolism by CYP2C9 and its allelic variants, CYP2C9*2 and CYP2C9*3
    Einolf, HJ
    Fischer, V
    DRUG METABOLISM REVIEWS, 2003, 35 : 191 - 191
  • [37] CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin
    Bland, TM
    Haining, RL
    Tracy, TS
    Callery, PS
    BIOCHEMICAL PHARMACOLOGY, 2005, 70 (07) : 1096 - 1103
  • [38] Variation in cytochrome P450 CYP2C19/CYP2C9 and efficacy of chlorproguanil and dapsone
    Janha, R.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2010, 15 (08) : S19 - S19
  • [39] CYP2C9 polymorphism and warfarin dose requirements
    Daly, AK
    Day, CP
    Aithal, GP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 408 - 409
  • [40] Application of Vivid™ fluorogenic substrates for the in vitro assessment of CYP2C9*1, CYP2C9*2 and CYP2C9*3 metabolism
    Thompson, DV
    Marks, BD
    Goossens, TA
    Trubetskoy, OV
    DRUG METABOLISM REVIEWS, 2002, 34 : 153 - 153